Copyright Reports & Markets. All rights reserved.

Phosphodiesterase Type 5 (PDE5) Inhibitor-Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Market Status and Trend Report 2013-2026

Request for Sample of this report
Buy now

Table of Contents

    1. Methodology and Scope

    • 1.1. Methodology
      • 1.1.1. Initial data exploration
      • 1.1.2. Statistical model and forecast
      • 1.1.3. Industry insights and validation
      • 1.1.4. Definitions forecast parameters
    • 1.2. Data sources
      • 1.2.1. Secondary
      • 1.2.2. Primary

    2 Market Overview

    • 2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 2.2 Market Analysis by Type
      • 2.2.1 Sildenafil
      • 2.2.2 Tadalafil
      • 2.2.3 Avanafil
      • 2.2.4 Vardenafil
    • 2.3 Market Analysis by Applications
      • 2.3.1 Hospital
      • 2.3.2 Retail Pharmacy
      • 2.3.3 Online Pharmacies
      • 2.3.4 Other
    • 2.4 Market Analysis by Regions
      • 2.4.1 North America (United States, Canada and Mexico)
        • 2.4.1.1 United States Market Status and Outlook (2013-2026)
        • 2.4.1.2 Canada Market Status and Outlook (2013-2026)
        • 2.4.1.3 Mexico Market Status and Outlook (2013-2026)
      • 2.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 2.4.2.1 Germany Market Status and Outlook (2013-2026)
        • 2.4.2.2 France Market Status and Outlook (2013-2026)
        • 2.4.2.3 UK Market Status and Outlook (2013-2026)
        • 2.4.2.4 Russia Market Status and Outlook (2013-2026)
        • 2.4.2.5 Italy Market Status and Outlook (2013-2026)
      • 2.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 2.4.3.1 China Market Status and Outlook (2013-2026)
        • 2.4.3.2 Japan Market Status and Outlook (2013-2026)
        • 2.4.3.3 Korea Market Status and Outlook (2013-2026)
        • 2.4.3.4 India Market Status and Outlook (2013-2026)
        • 2.4.3.5 Southeast Asia Market Status and Outlook (2013-2026)
      • 2.4.4 South America, Middle East and Africa
        • 2.4.4.1 Brazil Market Status and Outlook (2013-2026)
        • 2.4.4.2 Egypt Market Status and Outlook (2013-2026)
        • 2.4.4.3 Saudi Arabia Market Status and Outlook (2013-2026)
        • 2.4.4.4 South Africa Market Status and Outlook (2013-2026)
        • 2.4.4.5 Nigeria Market Status and Outlook (2013-2026)
    • 2.5 Market Dynamics
      • 2.5.1 Market Opportunities
      • 2.5.2 Market Risk
      • 2.5.3 Market Driving Force
    • 2.6 Market Competition News and Trend
      • 2.6.1 Merger, Consolidation or Acquisition News
      • 2.6.2 Investment or Disinvestment News
      • 2.6.3 New Product Development and Launch

    3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Revenue, Market Share and Competition by Manufacturer (2016-2018)

    • 3.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Market Share by Manufacturer (2016-2018)
    • 3.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Manufacturer (2016-2018)
    • 3.3 Market Concentration Rate
      • 3.3.1 Top 3 Phosphodiesterase Type 5 (PDE5) Inhibitor Manufacturer Market Share
      • 3.3.2 Top 6 Phosphodiesterase Type 5 (PDE5) Inhibitor Manufacturer Market Share
    • 3.4 Market Competition Trend

    4 Manufacturers Profiles

    • 4.1 Eli Lilly
      • 4.1.1 Business Overview
      • 4.1.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.1.2.1 Product A
        • 4.1.2.2 Product B
      • 4.1.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.2 AstraZeneca
      • 4.2.1 Business Overview
      • 4.2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.2.2.1 Product A
        • 4.2.2.2 Product B
      • 4.2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.3 Novartis AG
      • 4.3.1 Business Overview
      • 4.3.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.3.2.1 Product A
        • 4.3.2.2 Product B
      • 4.3.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.4 Pfizer
      • 4.4.1 Business Overview
      • 4.4.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.4.2.1 Product A
        • 4.4.2.2 Product B
      • 4.4.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.5 Roche
      • 4.5.1 Business Overview
      • 4.5.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.5.2.1 Product A
        • 4.5.2.2 Product B
      • 4.5.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.6 Bayer
      • 4.6.1 Business Overview
      • 4.6.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.6.2.1 Product A
        • 4.6.2.2 Product B
      • 4.6.3 Bayer Product Name Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.7 SK Chemicals
      • 4.7.1 Business Overview
      • 4.7.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.7.2.1 Product A
        • 4.7.2.2 Product B
      • 4.7.3 SK Chemicals Product Name Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.8 GlaxoSmithKline plc
      • 4.8.1 Business Overview
      • 4.8.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.8.2.1 Product A
        • 4.8.2.2 Product B
      • 4.8.3 GlaxoSmithKline plc Product Name Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.9 Merck
      • 4.9.1 Business Overview
      • 4.9.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.9.2.1 Product A
        • 4.9.2.2 Product B
      • 4.9.3 Merck Product Name Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.10 BaiYunShan General Factory
      • 4.10.1 Business Overview
      • 4.10.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.10.2.1 Product A
        • 4.10.2.2 Product B
      • 4.10.3 BaiYunShan General Factory Product Name Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.11 Vectura Group
      • 4.11.1 Business Overview
      • 4.11.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.11.2.1 Product A
        • 4.11.2.2 Product B
      • 4.11.3 Vectura Group Product Name Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.12 Teva Pharma
      • 4.12.1 Business Overview
      • 4.12.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.12.2.1 Product A
        • 4.12.2.2 Product B
      • 4.12.3 Teva Pharma Product Name Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.13 Seoul Pharma
      • 4.13.1 Business Overview
      • 4.13.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.13.2.1 Product A
        • 4.13.2.2 Product B
      • 4.13.3 Seoul Pharma Product Name Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.14 Dong-A ST
      • 4.14.1 Business Overview
      • 4.14.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.14.2.1 Product A
        • 4.14.2.2 Product B
      • 4.14.3 Dong-A ST Product Name Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)
    • 4.15 Metuchen Pharma
      • 4.15.1 Business Overview
      • 4.15.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications
        • 4.15.2.1 Product A
        • 4.15.2.2 Product B
      • 4.15.3 Metuchen Pharma Product Name Sales, Price, Revenue, Gross Margin and Market Share (2016-2018)

    5 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Analysis by Regions

    • 5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Revenue and Market Share by Regions
      • 5.1.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Market Share by Regions (2013-2018)
      • 5.1.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Regions (2013-2018)
    • 5.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 5.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 5.4 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 5.5 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 5.6 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)

    6 North America Phosphodiesterase Type 5 (PDE5) Inhibitor by Countries

    • 6.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Revenue and Market Share by Countries
      • 6.1.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Market Share by Countries (2013-2018)
      • 6.1.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Countries (2013-2018)
    • 6.2 United States Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 6.3 Canada Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 6.4 Mexico Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)

    7 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor by Countries

    • 7.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Revenue and Market Share by Countries
      • 7.1.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Market Share by Countries (2013-2018)
      • 7.1.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Countries (2013-2018)
    • 7.2 Germany Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 7.3 UK Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 7.4 France Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 7.5 Russia Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 7.6 Italy Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)

    8 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor by Countries

    • 8.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Revenue and Market Share by Countries
      • 8.1.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Market Share by Countries (2013-2018)
      • 8.1.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Countries (2013-2018)
    • 8.2 China Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 8.3 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 8.4 Korea Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 8.5 India Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 8.6 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)

    9 South America Phosphodiesterase Type 5 (PDE5) Inhibitor by Countries

    • 9.1 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Revenue and Market Share by Countries
      • 9.1.1 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Market Share by Countries (2013-2018)
      • 9.1.2 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Countries (2013-2018)
    • 9.2 Brazil Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 9.3 Argentina Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 9.4 Colombia Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)

    10 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor by Countries

    • 10.1 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Revenue and Market Share by Countries
      • 10.1.1 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Market Share by Countries (2013-2018)
      • 10.1.2 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Countries (2013-2018)
    • 10.2 Saudi Arabia Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 10.3 UAE Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 10.4 Egypt Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 10.5 Nigeria Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)
    • 10.6 South Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Growth Rate (2013-2018)

    11 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Segment by Type

    • 11.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Revenue and Market Share by Type (2013-2018)
      • 11.1.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Sales and Market Share by Type (2013-2018)
      • 11.1.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Type (2013-2018)
    • 11.2 Sildenafil Sales Growth Rate and Price
      • 11.2.1 Global Sildenafil Sales Growth Rate (2013-2018)
      • 11.2.2 Global SildenafilPrice (2013-2018)
    • 11.3 Tadalafil Sales Growth Rate and Price
      • 11.3.1 Global Tadalafil Sales Growth Rate (2013-2018)
      • 11.3.2 Global Tadalafil Price (2013-2018)
    • 11.4 Avanafil Sales Growth Rate and Price
      • 11.4.1 Global Avanafil Sales Growth Rate (2013-2018)
      • 11.4.2 Global Avanafil Price (2013-2018)
    • 11.5 Vardenafil Sales Growth Rate and Price
      • 11.5.1 Global Vardenafil Sales Growth Rate (2013-2018)
      • 11.5.2 Global Vardenafil Price (2013-2018)

    12 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Segment by Application

    • 12.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Application (2013-2018)
    • 12.2 Hospital Sales Growth Rate (2013-2018)
    • 12.3 Retail Pharmacy Sales Growth Rate (2013-2018)
    • 12.4 Online Pharmacies Sales Growth Rate (2013-2018)
    • 12.5 Other Sales Growth Rate (2013-2018)

    13 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast (2019-2026)

    • 13.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Sales, Revenue and Growth Rate (2019-2026)
    • 13.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast by Regions (2019-2026)
      • 13.2.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast (2019-2026)
      • 13.2.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast (2019-2026)
      • 13.2.3 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast (2019-2026)
      • 13.2.4 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast (2019-2026)
      • 13.2.5 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast (2019-2026)
    • 13.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast by Type (2019-2026)
      • 13.3.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Forecast by Type (2019-2026)
      • 13.3.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share Forecast by Type (2019-2026)
    • 13.4 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast by Application (2019-2026)
      • 13.4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Forecast by Application (2019-2026)
      • 13.4.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share Forecast by Application (2019-2026)

    14 Sales Channel, Distributors, Traders and Dealers

    • 14.1 Sales Channel
      • 14.1.1 Direct Marketing
      • 14.1.2 Indirect Marketing
      • 14.1.3 Marketing Channel Future Trend
    • 14.2 Market Positioning
      • 14.2.1 Pricing Strategy
      • 14.2.2 Brand Strategy
      • 14.2.3 Target Client
    • 14.3 Distributors, Traders and Dealers

    15 Research Findings and Conclusion

    Report Summary:
    The report titled "Phosphodiesterase Type 5 (PDE5) Inhibitor Market" offers a primary overview of the Phosphodiesterase Type 5 (PDE5) Inhibitor industry covering different product definitions, classifications, and participants in the industry chain structure. The quantitative and qualitative analysis is provided for the global Phosphodiesterase Type 5 (PDE5) Inhibitor market considering competitive landscape, development trends, and key critical success factors (CSFs) prevailing in the Phosphodiesterase Type 5 (PDE5) Inhibitor industry.
    Historical Forecast Period
    2013 - 2017 – Historical Year for Phosphodiesterase Type 5 (PDE5) Inhibitor Market
    2018 – Base Year for Phosphodiesterase Type 5 (PDE5) Inhibitor Market
    2019-2026 – Forecast Period for Phosphodiesterase Type 5 (PDE5) Inhibitor Market
    Key Developments in the Phosphodiesterase Type 5 (PDE5) Inhibitor Market
    To describe Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;
    To analyze the manufacturers of Phosphodiesterase Type 5 (PDE5) Inhibitor, with profile, main business, news, sales, price, revenue and market share in 2016 and 2018;
    To display the competitive situation among the top manufacturers in Global, with sales, revenue and market share in 2016 and 2018;
    To show the market by type and application, with sales, price, revenue, market share and growth rate by type and application, from 2013 to 2019;
    To analyze the key countries by manufacturers, Type and Application, covering North America, Europe, Asia Pacific, Middle-East and South America, with sales, revenue and market share by manufacturers, types and applications;
    Phosphodiesterase Type 5 (PDE5) Inhibitor market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2019 to 2026;
    To analyze the manufacturing cost, key raw materials and manufacturing process etc.
    To analyze the industrial chain, sourcing strategy and downstream end users (buyers);
    To describe Phosphodiesterase Type 5 (PDE5) Inhibitor sales channel, distributors, traders, dealers etc.
    To describe Phosphodiesterase Type 5 (PDE5) Inhibitor Research Findings and Conclusion, Appendix, methodology and data source
    Market Segment by Manufacturers, this report covers
    • Eli Lilly
    • AstraZeneca
    • Novartis AG
    • Pfizer
    • Roche
    • Bayer
    • SK Chemicals
    • GlaxoSmithKline plc
    • Merck
    • BaiYunShan General Factory
    • Vectura Group
    • Teva Pharma
    • Seoul Pharma
    • Dong-A ST
    • Metuchen Pharma
    Market Segment by Countries, covering
    • North America (United States, Canada, Mexico) Market Revenue and/or Volume
    Europe (Germany, UK, France, Russia, Italy) Market Revenue and/or Volume
    Asia Pacific (China, Japan, Korea, India, Southeast Asia) Market Revenue and/or Volume
    Middle-East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa) Market Revenue and/or Volume
    South America (Brazil, Argentina, Colombia) Market Revenue and/or Volume
    Market Segment by Type, covers
    • Sildenafil
    • Tadalafil
    • Avanafil
    • Vardenafil
    Market Segment by Applications, can be divided into
    • Hospital
    • Retail Pharmacy
    • Online Pharmacies
    • Other
    _x000C_

    Buy now